BRAF (G469A)

BRAF · Variant type: point · HGVS: p.G469A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Encorafenib	99.3%	0.7%	98.50
2	Dabrafenib	99.3%	0.7%	94.74
3	Ripretinib	98.8%	1.2%	92.95
4	Vemurafenib	97.7%	2.3%	96.49
5	Sorafenib	97.6%	2.4%	96.72
6	Regorafenib	97.3%	2.7%	95.99
7	Ponatinib	97.0%	3.0%	78.23
8	Tivozanib	92.7%	7.3%	92.42
9	Apatinib	91.9%	8.1%	97.73
10	Nilotinib	89.0%	11.0%	96.49
11	Rabusertib	87.7%	12.3%	98.74
12	Dasatinib	86.5%	13.5%	87.97
13	Pazopanib	79.7%	20.3%	97.49
14	Umbralisib	73.0%	27.0%	98.74
15	Erdafitinib	68.4%	31.6%	95.71
16	Ibrutinib	67.3%	32.7%	94.74
17	Upadacitinib	57.9%	42.1%	97.98
18	Lenvatinib	52.7%	47.3%	97.74
19	Imatinib	40.2%	59.8%	99.00
20	Pacritinib	34.4%	65.6%	88.64
21	Dacomitinib	32.3%	67.7%	97.99
22	Paxalisib	32.2%	67.8%	99.75
23	Canertinib	30.3%	69.7%	96.49
24	Fedratinib	29.9%	70.1%	96.21
25	Vandetanib	29.1%	70.9%	95.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Encorafenib	99.3%	98.0%	+1.3%
Dabrafenib	99.3%	98.3%	+1.0%
Ripretinib	98.8%	100.0%	-1.2%
Vemurafenib	97.7%	92.8%	+4.9%
Sorafenib	97.6%	98.5%	-1.0%
Regorafenib	97.3%	98.3%	-1.0%
Ponatinib	97.0%	99.4%	-2.5%
Tivozanib	92.7%	41.8%	+50.9%
Apatinib	91.9%	94.1%	-2.2%
Nilotinib	89.0%	85.8%	+3.2%
Rabusertib	87.7%	41.1%	+46.7%
Dasatinib	86.5%	80.6%	+5.9%
Pazopanib	79.7%	79.3%	+0.4%
Umbralisib	73.0%	65.3%	+7.8%
Erdafitinib	68.4%	54.1%	+14.3%
Ibrutinib	67.3%	—	—
Upadacitinib	57.9%	49.6%	+8.3%
Lenvatinib	52.7%	—	—
Imatinib	40.2%	—	—
Pacritinib	34.4%	58.5%	-24.1%
Dacomitinib	32.3%	46.6%	-14.3%
Paxalisib	32.2%	—	—
Canertinib	30.3%	40.7%	-10.3%
Fedratinib	29.9%	—	—
Vandetanib	29.1%	—	—

Cancer	Organ	Source
Lung Cancer	Lung	ref
Myeloma	Blood/Lymphatic System	ref
Unknown	Other	ref
carcinoma_lung	Lung	ref
carcinoma_large_intestine	Large Intestine	ref
carcinoma_oesophagus	Stomach/Digestive Tract	ref
lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue	Blood/Lymphatic System	ref
malignant_melanoma_skin	Skin	ref
carcinoma_thyroid	Thyroid	ref
carcinoma_upper_aerodigestive_tract	Brain/CNS	ref
carcinoma_urinary_tract	Bladder	ref
serrated_polyp_large_intestine	Large Intestine	ref
carcinoma_stomach	Stomach/Digestive Tract	ref
carcinoma_small_intestine	Small Intestine	ref
carcinoma_prostate	Prostate	ref
haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue	Blood/Lymphatic System	ref
carcinoma_biliary_tract	Biliary Tract	ref
malignant_melanoma_eye	Brain/CNS	ref
adenoma_small_intestine	Small Intestine	ref
carcinoma_breast	Breast	ref
malignant_melanoma_NS	Skin	ref
carcinoma_NS	Other	ref
glioma_central_nervous_system	Brain/CNS	ref
BLCA-CN	Bladder	ref
BLCA-US	Bladder	ref
CLLE-ES	Blood/Lymphatic System	ref
COAD-US	Large Intestine	ref
EOPC-DE	Pancreas	ref
LUAD-US	Lung	ref
LUSC-US	Lung	ref
ORCA-IN	Ovary	ref
PRAD-US	Prostate	ref
SKCA-BR	Skin	ref
SKCM-US	Skin	ref
STAD-US	Stomach/Digestive Tract	ref
BLCA	Bladder	ref
COAD	Large Intestine	ref
LUAD	Lung	ref
LUSC	Lung	ref
PCPG	Adrenal	ref
PRAD	Prostate	ref
SKCM	Skin	ref
STAD	Stomach/Digestive Tract	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 28.5ms